Island Pharmaceuticals Secures Strategic Agreement with Texas Biomed for Galidesivir Program
Island Pharmaceuticals Limited entered into a Master Service Agreement (MSA) with the Texas Biomedical Research Institute to advance its lead antiviral candidate, galidesivir, by leveraging Texas Biomed’s Biosafety Level 4 (BSL-4) facilities and non-human primate research capabilities, crucial for regulatory approval under the FDA’s Animal Rule pathway. The collaboration is aimed at supporting potential primate studies and aligns with recent FDA feedback confirming eligibility for this development route and the possibility of a Priority Review Voucher upon approval. Texas Biomed’s expertise in high-containment infectious disease research provides Island with strategic optionality as it plans further study designs and prepares for a potential clinical program in early 2026.This agreement reinforces Island’s focus on addressing unmet public health needs posed by high-consequence viral threats. 
Island Pharmaceuticals Secures Strategic Agreement with Texas Biomed for Galidesivir Program